| Gateway Foot And Ankle Center, Plc | |
|
313 N Main St., Suite 1j, Ashland City, TN 37015-1347 | |
| (931) 245-1920 | |
| Not Available |
| Full Name | Gateway Foot And Ankle Center, Plc |
|---|---|
| Type | Facility |
| Speciality | Podiatrist - Foot & Ankle Surgery |
| Location | 313 N Main St., Ashland City, Tennessee |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245660869 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Gateway Foot And Ankle Center, Plc 647 Dunlop Ln, Suite 209, Clarksville, TN 37040-5165 Ph: () - | Gateway Foot And Ankle Center, Plc 313 N Main St., Suite 1j, Ashland City, TN 37015-1347 Ph: (931) 245-1920 |
News Archive
The Michael J. Fox Foundation for Parkinson's Research today announced nearly $1.1 million for projects aimed at advancing the development of leading biomarker candidates for Parkinson's disease. The discovery and validation of biomarkers is of critical importance to increasing the speed and efficiency of PD therapeutic development, allowing scientists and clinicians to more accurately identify appropriate subjects for clinical studies, measure disease progression and monitor treatment effects in clinical trials.
Coastal Contacts Inc. today announced that it has entered into a loan agreement with the Bank of America for a $5 million secured revolving line of credit.
Millions of people have contracted Zika and chikungunya virus infections since the outbreaks that have been striking Latin America since 2013. Particularly Zika-related malformations in newborns warrant reliable diagnostics.
Researchers have developed an implant that has shown promise for reducing addiction rates. However, there are major ethical and financial concerns, which we have tried to cover in this news story.
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial with aldoxorubicin for the treatment of unresectable glioblastoma multiforme (GBM), a deadly form of brain cancer.
› Verified 6 days ago
Gateway Foot And Ankle Center, Plc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 313 N Main St, Suite 1j, Ashland City, TN 37015 Phone: 931-245-1920 |